Novo Nordisk A/S found using ticker (NVO) have now 5 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 159.57 and 119.38 with a mean TP of 140.25. Now with the previous closing price of 139.08 this is indicating there is a potential upside of .8%. There is a 50 day moving average of 132.24 and the 200 moving average now moves to 114.29. The market capitalisation for the company is $297,549m. Find out more information at: https://www.novonordisk.com
The potential market cap would be $300,052m based on the market concensus.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences Novo Nordisk A/S also has a research collaboration with Lumen Bioscience to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
